20/20 BioLabs Recommends Stock Split to Stay Nasdaq Compliant

GAITHERSBURG, Md., Nov. 05, 2026 /CourierPR/ -- The Board of Directors of 20/20 BioLabs, Inc. has recommended a vote in favor of two proposals at the upcoming Special Meeting of Stockholders, scheduled for December 9, 2026. The first proposal is for the authorization of the Company’s Board of Directors to implement one or more reverse stock splits of the Company’s outstanding common stock, each at a ratio of not less than 1-for-2 and not more than 1-for-250, at any time prior to December 31, 2028. The second proposal is for the approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies.

The Board of Directors recommends a vote in favor of both proposals. The reverse stock split authorization is intended to provide the Board of Directors with the flexibility to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The record date for the meeting is October 20, 2026, and stockholders of record as of that date are entitled to vote.

Stockholders can vote their shares online, by phone, or by fax in advance of the 10:00 a.m. Eastern Time live webcast of the meeting, which will be held on December 9, 2026. The meeting will be held virtually, and stockholders will need the control number included on their notice card, proxy card, or voting instruction form to participate in the webcast.

The Special Meeting is scheduled to begin at 10:00 a.m. Eastern Time. The Company encourages stockholders to vote in advance, even if they plan to attend the meeting, to ensure their shares are represented.

20/20 BioLabs, Inc., an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, is listed on the Nasdaq under the ticker symbol AIDX. The Company offers two families of lab tests under the OneTest brand, including OneTest™ for Cancer, a multi-cancer early detection blood test, and OneTest™ for Longevity, which measures inflammatory biomarkers and is commercially available.

Certain statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, as well as in its other reports filed or furnished from time to time with the SEC.